FDA Expands Wegovy Approval to Include Cardiovascular Disease Reduction

Key points

• The FDA approved Wegovy to reduce the risk of heart attacks, strokes, and cardiac death in overweight adults with cardiovascular disease.
• Clinical trials showed a twenty percent reduction in major adverse cardiovascular events among participants taking the medication.
• The new approval enables Medicare and private insurers to cover the drug under cardiac health benefits rather than restricted weight-loss categories.
• Growing usage of GLP-1 drugs is continuing to reshape food industry trends, consumer spending, and restaurant menu sizing.

This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.

Sources and methodology

Reported from the public datasets below.

• Bureau of Labor Statistics (BLS) - Consumer Price Index, food away from home
• Federal Reserve Economic Data (FRED) - Food services and drinking places series
• U.S. Census Bureau - Monthly Retail Trade, food services

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

• UK Food Inflation Tops European Leaderboards as Supermarket Baskets Soar
• FDA Expands Wegovy Label to Include Heart Attack and Stroke Reduction
• Celebrity Chef Opening Marks Major Economic Level Up for Arlington Restaurant Scene
• Inside The Cocochine: How Mayfair Newest Luxury Table Strategy Unfolds
• FDA Approves Wegovy for Heart Disease Risk Reduction as Food Industry Prepares for Shift